Form 4: Teladoc Health Executive Trades TDOC Shares

Adam C. Vandervoort, Chief Legal Officer of Teladoc Health, Inc., reported transactions involving the acquisition and disposition of company stock.

Summary

• Adam C. Vandervoort, Chief Legal Officer and Secretary of Teladoc Health, Inc., reported several transactions on June 1st and June 2nd, 2026.
• These transactions include the acquisition of 426 performance stock units and 5,350 restricted stock units on June 1st, 2026.
• Additionally, 9,152 restricted stock units were acquired on the same date.
• On June 2nd, 2026, 7,906 shares were disposed of at a price of $7.627 per share.
• Following these transactions, Mr. Vandervoort beneficially owns 110,261 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine executive stock transactions related to compensation and tax obligations, rather than significant strategic shifts or performance indicators.

Positives

• Acquisition of 426 performance stock units on June 1, 2026.
• Acquisition of 5,350 restricted stock units on June 1, 2026.
• Acquisition of 9,152 restricted stock units on June 1, 2026.

Negatives

• Disposition of 7,906 shares on June 2, 2026, at $7.627 per share, likely to cover tax withholding obligations.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive stock dealings within the telehealth and digital health industry.

Stakeholder Impact

• Shareholders: Increased transparency into executive stock ownership and transactions.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Teladoc Health, TDOC, Stock Transaction, Executive Compensation, Restricted Stock Units, Performance Stock Units